StockNews.com assumed coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a report released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Vascular Biogenics Price Performance
NASDAQ:VBLT remained flat at $0.14 during trading hours on Friday. The company had a trading volume of 1,027,376 shares, compared to its average volume of 10,688,738. The stock has a fifty day simple moving average of $0.15 and a two-hundred day simple moving average of $0.15. Vascular Biogenics has a fifty-two week low of $0.10 and a fifty-two week high of $2.20.
Institutional Trading of Vascular Biogenics
Large investors have recently bought and sold shares of the business. Group One Trading L.P. boosted its stake in Vascular Biogenics by 62.0% in the third quarter. Group One Trading L.P. now owns 293,118 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 112,148 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Vascular Biogenics in the third quarter valued at about $52,000. Telemetry Investments L.L.C. raised its position in Vascular Biogenics by 239.0% in the third quarter. Telemetry Investments L.L.C. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 282,000 shares during the last quarter. Envestnet Asset Management Inc. bought a new position in Vascular Biogenics in the first quarter valued at about $64,000. Finally, Two Sigma Investments LP bought a new position in Vascular Biogenics in the third quarter valued at about $66,000. 4.81% of the stock is owned by institutional investors and hedge funds.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
- Get a free copy of the StockNews.com research report on Vascular Biogenics (VBLT)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.